Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis

Andrew M Moon, Amit G Singal, Elliot B Tapper, Andrew M Moon, Amit G Singal, Elliot B Tapper

Abstract

Background & aims: Accurate estimates for the contemporary burden of chronic liver disease (CLD) are vital for setting clinical, research, and policy priorities. We aimed to review the incidence, prevalence, and mortality of CLD and its resulting complications, including cirrhosis and hepatocellular carcinoma (HCC).

Methods: We reviewed the published literature on the incidence, prevalence, trends of various etiologies of CLD and its resulting complications. In addition, we provided updated data from the Centers for Disease Control and Global Burden of Disease Study on the morbidity and mortality of CLD, cirrhosis, and hepatocellular carcinoma (HCC). Lastly, we assessed the strengths and weaknesses of available sources of data in hopes of providing important context to these national estimates of cirrhosis burden.

Results: An estimated 1.5 billion persons have CLD worldwide and the age-standardized incidence of CLD and cirrhosis is 20.7/100,000, a 13% increase since 2000. Similarly, cirrhosis prevalence and mortality has increased in recent years in the United States. The epidemiology of CLD is shifting, reflecting implementation of large-scale hepatitis B vaccination and hepatitis C treatment programs, the increasing prevalence of the metabolic syndrome, and increasing alcohol misuse.

Conclusions: The global burden of CLD and cirrhosis is substantial. Although vaccination, screening, and antiviral treatment campaigns for hepatitis B and C have reduced the CLD burden in some parts of the world, concomitant increases in injection drug use, alcohol misuse, and metabolic syndrome threaten these trends. Ongoing efforts to address CLD-related morbidity and mortality require accurate contemporary estimates of epidemiology and outcomes.

Keywords: Alcohol-related; Hepatitis B; Hepatitis C; Liver Cancer; Nonalcoholic Fatty Liver Disease.

Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1:. Global Burden of Cirrhosis Mortality
Figure 1:. Global Burden of Cirrhosis Mortality
In this figure, abstracted from the Global Burden of Disease Study (https://vizhub.healthdata.org/gbd-compare/. accessed 4/2/19), we detail the age-adjusted risk of mortality (per 100,000 persons) attributed to cirrhosis. Legend (mortality per 100,000 persons): Dark to light blue (0-40). Yellow (40-50), Yellow-Orange (50-60), Orange-Red (60-70), Red (>70)
Figure 2:. Global Burden of Years Lost…
Figure 2:. Global Burden of Years Lost to Disability Due to Cirrhosis
In this this figure, we detail the years lost to disability (YLD) due to cirrhosis. YLD is a function of the disease incidence, the disability weight (on functioning) and the average duration of illness. Data abstracted from the Global Burden of Disease Study (https://vizhub.healthdata.org/gbd-compare/, accessed 4/2/19).
Figure 3:. Mortality Due to Chronic Liver…
Figure 3:. Mortality Due to Chronic Liver Disease (CLD), Cirrhosis and Hepatocellular Carcinoma (HCC) in the US (1999-2017)
In the left panel we show how the age-adjusted mortality for CLD, cirrhosis, and HCC has changed over time. While HCC-related mortality has slowly climbed from 1999, mortality due to CLD and cirrhosis began rising after 2008, continuously through 2017 In the right panel we show the raw numbers of deaths attributed primarily to CLD, cirrhosis, and HCC for each year from 1999-2017

References

    1. Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 2014;12:145.
    1. Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ 2018;362:k2817.
    1. Asrani SK, Larson JJ, Yawn B, et al. Underestimation of liver-related mortality in the United States. Gastroenterology 2013;145:375–82 e1-2.
    1. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789–1858.
    1. Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol 2018;69:718–735.
    1. Byass P The global burden of liver disease: a challenge for methods and for public health. BMC Med 2014;12:159.
    1. Wong MCS, Huang JLW, George J, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol 2019;16:57–73.
    1. Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol 2019;70:531–544.
    1. Liangpunsakul S, Haber P, McCaughan GW. Alcoholic Liver Disease in Asia, Europe, and North America. Gastroenterology 2016;150:1786–97.
    1. Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol 2019;70:151–171.
    1. Choi J, Han S, Kim N, et al. Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population. Hepatology 2017;66:1454–1463.
    1. Hadler SC, Fuqiang C, Averhoff F, et al. The impact of hepatitis B vaccine in China and in the China GAVI Project. Vaccine 2013;31 Suppl 9:J66–72.
    1. Flemming JA, Dewit Y, Mah JM, et al. Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. Lancet Gastroenterol Hepatol 2018.
    1. Beste LA, Leipertz SL, Green PK, et al. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology 2015; 149:1471–1482 e5; quiz e17-8.
    1. Scaglione S, Kliethermes S, Cao G, et al. The Epidemiology of Cirrhosis in the United States: A Population-based Study. J Clin Gastroenterol 2015;49:690–6.
    1. Kanwal F, Kramer JR, Duan Z, et al. Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans. Clin Gastroenterol Hepatol 2016;14:301–8 e1-2.
    1. Moon AM, Green PK, Berry K, et al. Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. Aliment Pharmacol Ther 2017;45:1201–1212.
    1. Younossi Z, Tacke F, Arrese M, et al. Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. Hepatology 2018.
    1. Sayiner M, Koenig A, Henry L, et al. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis 2016;20:205–14.
    1. Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017;153:996–1005. e1.
    1. Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016. Hepatology 2018.
    1. Mokdad AH, Forouzanfar MH, Daoud F, et al. Global burden of diseases, injuries, and risk factors for young people's health during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2016;387:2383–401.
    1. Falla AM, Hofstraat SHI, Duffell E, et al. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis 2018;18:79.
    1. World Health Organization. Global hepatitis report 2017. Volume 2019, 2017.
    1. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014;160:293–300.
    1. Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161–176.
    1. Centers for Disease Control and Prevention (CDC). Viral Hepatitis Surveillance United States, 2016. Volume 2019, 2018.
    1. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016;388:1081–1088.
    1. Wong RJ, Jain MK, Therapondos G, et al. Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment. Am J Gastroenterol 2018;113:1329–1338.
    1. IMS Health. Medicines Use and Spending Shifts In: Informatics IIfH, ed. Parsippany, NJ: IMS Institute, 2015.
    1. Elsharkawy A, El-Raziky M, El-Akel W, et al. Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. J Hepatol 2018;68:691–698.
    1. Scott N, Olafsson S, Gottfreethsson M, et al. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020. J Hepatol 2018;68:932–939.
    1. Chikovani I, Ompad DC, Uchaneishvili M, et al. On the way to Hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study. PLoS One 2019;14:e0216123.
    1. Jain MK, Rich NE, Ahn C, et al. Evaluation of a Multifaceted Intervention to Reduce Health Disparities in Hepatitis C Screening: A Pre-Post Analysis. Hepatology 2019.
    1. Cooke GS, Andrieux-Meyer I, Applegate TL, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol 2019;4:135–184.
    1. Yehia BR, Schranz AJ, Umscheid CA, et al. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One 2014;9:e101554.
    1. Wiessing L, Ferri M, Grady B, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One 2014;9:e103345.
    1. Marshall AD, Cunningham EB, Nielsen S, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol 2018;3:125–133.
    1. National Viral Hepatitis Roundtable. Hepatitis C: The State of Medicaid Access In: Innovation CfHLaP, ed: Harvard Law School, 2017.
    1. Kim HS, Yang JD, El-Serag HB, et al. Awareness of Chronic Viral Hepatitis in the United States: An Update from National Health and Nutrition Examination Survey. J Viral Hepat 2019.
    1. Kasting ML, Giuliano AR, Reich RR, et al. Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. Cancer Epidemiol Biomarkers Prev 2018;27:503–513.
    1. Goldberg D, Ditah IC, Saeian K, et al. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology 2017;152:1090–1099 e1.
    1. Morse A, Barritt ASt, Jhaveri R Individual State Hepatitis C Data Supports Expanding Screening Beyond Baby Boomers to All Adults. Gastroenterology 2018;154:1850–1851 e2.
    1. Moon AM, Green PK, Berry K, et al. Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. Alimentary pharmacology & therapeutics 2017;45:1201–1212.
    1. Ott JJ, Horn J, Krause G, et al. Time trends of chronic HBV infection over prior decades - A global analysis. J Hepatol 2017;66:48–54.
    1. Le MH, Yeo YH, Cheung R, et al. Chronic hepatitis B prevalence among foreign-born and US-born adults in the United States, 1999-2016. Hepatology.
    1. Brown RS Jr, McMahon BJ, Lok AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology 2016;63:319–33.
    1. Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386:1546–55.
    1. Uribe LA, Nguyen N, Kim L, et al. Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation. Dig Dis Sci 2016;61:618–25.
    1. Hutin Y, Nasrullah M, Easterbrook P, et al. Access to Treatment for Hepatitis B Virus Infection - Worldwide, 2016. MMWR Morb Mortal Wkly Rep 2018;67:773–777.
    1. Kabbany MN, Conjeevaram Selvakumar PK, Watt K, et al. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Am J Gastroenterol 2017;112:581–587.
    1. Allen AM, Therneau TM, Larson JJ, et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology 2018;67:1726–1736.
    1. Balp M-M, Krieger N, Przybysz R, et al. The burden of nonalcoholic steatohepatitis (NASH) among patients from Europe: a real-world patient-reported outcomes study. JHEP Reports 2019.
    1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84.
    1. Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019.
    1. Rich NE, Oji S, Mufti AR, et al. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2018;16:198–210 e2.
    1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387–95.
    1. Bedogni G, Miglioli L, Masutti F, et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007;46:1387–91.
    1. Zhou YJ, Li YY, Nie YQ, et al. Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. J Dig Dis 2012; 13:153–60.
    1. Wong VW, Wong GL, Yeung DK, et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol 2015;62:182–9.
    1. Zelber-Sagi S, Salomone F, Yeshua H, et al. Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease. Liver Int 2014;34:e128–35.
    1. Chang Y, Jung HS, Cho J, et al. Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2016;111:1133–40.
    1. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012;307:483–90.
    1. Zimmermann E, Gamborg M, Holst C, et al. Body mass index in school-aged children and the risk of routinely diagnosed non-alcoholic fatty liver disease in adulthood: a prospective study based on the Copenhagen School Health Records Register. BMJ Open 2015;5:e006998.
    1. Hagstrom H, Stal P, Hultcrantz R, et al. Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study. J Hepatol 2016;65:363–8.
    1. Anderson EL, Howe LD, Jones HE, et al. The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. PLoS One 2015;10:e0140908.
    1. Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123–133.
    1. Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol 2013;59:160–8.
    1. Sheron N. Alcohol and liver disease in Europe--Simple measures have the potential to prevent tens of thousands of premature deaths. J Hepatol 2016;64:957–67.
    1. Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1151–1210.
    1. Mellinger JL, Shedden K, Winder GS, et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology 2018;68:872–882.
    1. World Health Organization. Global status report on alcohol and health, 2018.
    1. Wong T, Dang K, Ladhani S, et al. Prevalence of Alcoholic Fatty Liver Disease Among Adults in the United States, 2001-2016. JAMA 2019;321:1723–1725.
    1. Yang AL, Vadhavkar S, Singh G, et al. Epidemiology of alcohol-related liver and pancreatic disease in the United States. Arch Intern Med 2008;168:649–56.
    1. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011;141:1572–85.
    1. Simpson RF, Hermon C, Liu B, et al. Alcohol drinking patterns and liver cirrhosis risk: analysis of the prospective UK Million Women Study. Lancet Public Health 2019;4:e41–e48.
    1. Huang A, Chang B, Sun Y, et al. Disease spectrum of alcoholic liver disease in Beijing 302 Hospital from 2002 to 2013: A large tertiary referral hospital experience from 7422 patients. Medicine (Baltimore) 2017;96:e6163.
    1. Damgaard Sandahl T Alcoholic hepatitis. Dan Med J 2014;61:B4755.
    1. Shah ND, Ventura-Cots M, Abraldes JG, et al. Alcohol-related Liver Disease is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. Clin Gastroenterol Hepatol 2019.
    1. Flemming JA, Dewit Y, Mah JM, et al. Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. The Lancet Gastroenterology & Hepatology 2018.
    1. Collaborators GBDA. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2018;392:1015–1035.
    1. Mehta G, Sheron N. No safe level of alcohol consumption - Implications for global health. J Hepatol 2019.
    1. Kim WR, Lindor KD, Locke GR 3rd, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000; 119:1631–6.
    1. Hurlburt KJ, McMahon BJ, Deubner H, et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002;97:2402–7.
    1. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012;56:1181–8.
    1. Lu M, Zhou Y, Haller IV, et al. Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment. Clin Gastroenterol Hepatol 2018; 16:1342–1350 e1.
    1. Murillo Perez CF, Goet JC, Lammers WJ, et al. Milder disease stage in patients with primary biliary cholangitis over a 44D-year period: A changing natural history. Hepatology 2018;67:1920–1930.
    1. Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004;126:1929–30.
    1. Lindkvist B, Benito de Valle M, Gullberg B, et al. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 2010;52:571–7.
    1. Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;125:1364–9.
    1. Gronbaek L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 2014;60:612–7.
    1. Feld JJ, Heathcote EJ. Epidemiology of autoimmune liver disease. J Gastroenterol Hepatol 2003;18:1118–28.
    1. Werner M, Prytz H, Ohlsson B, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008;43:1232–40.
    1. Ngu JH, Bechly K, Chapman BA, et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol 2010;25:1681–6.
    1. Delgado JS, Vodonos A, Malnick S, et al. Autoimmune hepatitis in southern Israel: a 15-year multicenter study. J Dig Dis 2013; 14:611–8.
    1. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005;352:1769–78.
    1. Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211–8.
    1. Adams PC, Passmore L, Chakrabarti S, et al. Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 2006;4:918–23; quiz 807.
    1. McCune CA, Al-Jader LN, May A, et al. Hereditary haemochromatosis: only 1% of adult HFEC282Y homozygotes in South Wales have a clinical diagnosis of iron overload. Hum Genet 2002;111:538–43.
    1. Coffey AJ, Durkie M, Hague S, et al. A genetic study of Wilson's disease in the United Kingdom. Brain 2013;136:1476–87.
    1. Tapper EB, Rahni DO, Arnaout R, et al. The overuse of serum ceruloplasmin measurement. Am J Med 2013;126:926 e1–5.
    1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–50.
    1. Global Burden of Disease Liver Cancer C, Akinyemiju T, Abera S, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol 2017;3:1683–1691.
    1. Sun Z, Chen T, Thorgeirsson SS, et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis 2013;34:1800–5.
    1. Altekruse SF, Henley SJ, Cucinelli JE, et al. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 2014;109:542–53.
    1. White DL, Thrift AP, Kanwal F, et al. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology 2017;152:812–820 e5.
    1. Rich NE, Yopp AC, Singal AG, et al. Hepatocellular Carcinoma Incidence Is Decreasing Among Younger Adults in the United States. Clin Gastroenterol Hepatol 2019.
    1. Ioannou GN, Green PK, Beste LA, et al. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol 2018;69:1088–1098.
    1. El-Serag HB, Lau M, Eschbach K, et al. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med 2007;167:1983–9.
    1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264–1273 e1.
    1. Rich NE, Hester C, Odewole M, et al. Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2019;17:551–559 e1.
    1. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217–31.
    1. D'Amico G, Morabito A, D'Amico M, et al. Clinical states of cirrhosis and competing risks. J Hepatol 2018;68:563–576.
    1. D'Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 2014;39:1180–93.
    1. Ratib S, Fleming KM, Crooks CJ, et al. Causes of death in people with liver cirrhosis in England compared with the general population: a population-based cohort study. Am J Gastroenterol 2015;110:1149–58.
    1. Fleming KM, Aithal GP, Card TR, et al. The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Aliment Pharmacol Ther 2010;32:1343–50.
    1. Tapper EB, Parikh ND, Sengupta N, et al. A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis. 2018;68:1498–1507.
    1. Fleming KM, Aithal GP, Card TR, et al. All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver Int 2012;32:79–84.
    1. Peery AF, Crockett SD, Murphy CC, et al. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. Gastroenterology 2019;156:254–272 e11.
    1. Piano S, Brocca A, Mareso S, et al. Infections complicating cirrhosis. Liver Int 2018;38 Suppl 1:126–133.
    1. Piano S, Singh V, Caraceni P, et al. Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology 2019;156:1368–1380 e10.
    1. Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015;62:968–74.
    1. Montoliu S, Balleste B, Planas R, et al. Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites. Clin Gastroenterol Hepatol 2010;8:616–22; quiz e80.
    1. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008;48:2064–77.
    1. Piano S, Rosi S, Maresio G, et al. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol 2013;59:482–9.
    1. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229–36.
    1. Martin-Llahi M, Guevara M, Torre A, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011;140:488–496 e4.
    1. Lai JC, Feng S, Terrault NA, et al. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant 2014;14:1870–9.
    1. Lai JC, Covinsky KE, Dodge JL, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 2017;66:564–574.
    1. Laube R, Wang H, Park L, et al. Frailty in advanced liver disease. Liver Int 2018;38:2117–2128.
    1. Tapper EB, Risech-Neyman Y, Sengupta N. Psychoactive Medications Increase the Risk of Falls and Fall-related Injuries in Hospitalized Patients With Cirrhosis. Clin Gastroenterol Hepatol 2015;13:1670–5.
    1. Tapper EB, Baki J, Parikh ND, et al. Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patient-Reported Outcomes in Cirrhosis. Hepatology 2018.
    1. Rakoski MO, McCammon RJ, Piette JD, et al. Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study. Hepatology 2012;55:184–91.
    1. Lai JC, Dodge JL, Sen S, et al. Functional decline in patients with cirrhosis awaiting liver transplantation: Results from the functional assessment in liver transplantation (FrAILT) study. Hepatology 2016;63:574–80.
    1. Lai JC, Volk ML, Strasburg D, et al. Performance-Based Measures Associate With Frailty in Patients With End-Stage Liver Disease. Transplantation 2016;100:2656–2660.
    1. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426–37, 1437 e1-9.
    1. Arroyo V, Moreau R, Jalan R, et al. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. J Hepatol 2015;62: S131–43.
    1. Hernaez R, Sola E, Moreau R, et al. Acute-on-chronic liver failure: an update. Gut 2017;66:541–553.
    1. Bajaj JS, O'Leary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 2014;60:250–6.
    1. Hernaez R, Kramer JR, Liu Y, et al. Prevalence and short-term mortality in a national US cohort with acute-on-chronic liver failure. J Hepatol 2018.
    1. Gustot T, Fernandez J, Garcia E, et al. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015;62:243–52.
    1. Allen AM, Kim WR, Moriarty JP, et al. Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. Hepatology 2016;64:2165–2172.
    1. Asrani SK, Hall L, Hagan M, et al. Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study. Am J Gastroenterol 2019;114:98–106.
    1. Stepanova M, De Avila L, Afendy M, et al. Direct and Indirect Economic Burden of Chronic Liver Disease in the United States. Clin Gastroenterol Hepatol 2017;15:759–766 e5.
    1. Tapper EB, Bonder A, Cardenas A. Preventing and treating acute kidney injury among hospitalized patients with cirrhosis and ascites: a narrative review. The American journal of medicine 2016;129:461–467.
    1. Tapper EB, Halbert B, Mellinger J. Rates of and Reasons for Hospital Readmissions in Patients With Cirrhosis: A Multistate Population-based Cohort Study. Clin Gastroenterol Hepatol 2016;14:1181–1188 e2.
    1. Tapper EB, Volk M. Strategies to Reduce 30-Day Readmissions in Patients with Cirrhosis. Curr Gastroenterol Rep 2017; 19:1.
    1. Bajaj JS, Wade JB, Gibson DP, et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol 2011;106:1646–53.
    1. Tapper E, Kanwal F, Asrani S, et al. Patient Reported Outcomes in Cirrhosis: A Scoping Review of the Literature. Hepatology (Baltimore, Md.) 2017.
    1. Boscarino JA, Lu M, Moorman AC, et al. Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the Chronic Hepatitis Cohort Study (CHeCS). Hepatology 2015;61:802–811.
    1. Jepsen P, Ott P, Andersen PK, et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010;51:1675–82.
    1. Deleuran T, Vilstrup H, Jepsen P. Decreasing Mortality Among Danish Alcoholic Cirrhosis Patients: A Nationwide Cohort Study. Am J Gastroenterol 2016;111:817–22.
    1. Kanwal F, Volk M, Singal A, et al. Improving quality of health care for patients with cirrhosis. Gastroenterology 2014; 147:1204–7.
    1. World Health Organization. WHO calls for better monitoring of viral hepatitis and liver cancer. Volume 2019, 2018.
    1. Parkin DM. The evolution of the population-based cancer registry. Nat Rev Cancer 2006;6:603–12.
    1. Ratib S, West J, Fleming KM. Liver cirrhosis in England-an observational study: are we measuring its burden occurrence correctly? BMJ Open 2017;7:e013752.
    1. Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016;64:1577–1586.
    1. Kanerva N, Sandboge S, Kaartinen NE, et al. Higher fructose intake is inversely associated with risk of nonalcoholic fatty liver disease in older Finnish adults. Am J Clin Nutr 2014;100:1133–8.
    1. Riquelme A, Arrese M, Soza A, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int 2009;29:82–8.
    1. Roberts H, Kruszon-Moran D, Ly KN, et al. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988-2012. Hepatology 2016;63:388–97.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit